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Abstract: Background: Ventilator-associated pneumonia (VAP) is associated to longer stay and poor
outcomes. Lacking definitive diagnostic criteria, worsening gas exchange assessed by PaO2/FIO2 ≤ 240
in mmHg has been proposed as one of the diagnostic criteria for VAP. We aim to assess the adequacy
of PaO2/FIO2 ≤ 240 to diagnose VAP. Methods: Prospective observational study in 255 consecutive
patients with suspected VAP, clustered according to PaO2/FIO2 ≤ 240 vs. > 240 at pneumonia onset.
The primary analysis was the association between PaO2/FIO2 ≤ 240 and quantitative microbiologic
confirmation of pneumonia, the most reliable diagnostic gold-standard. Results: Mean PaO2/FIO2 at
VAP onset was 195 ± 82; 171 (67%) cases had PaO2/FIO2 ≤ 240. Patients with PaO2/FIO2 ≤ 240 had a
lower APACHE-II score at ICU admission; however, at pneumonia onset they had higher CPIS, SOFA
score, acute respiratory distress syndrome criteria and incidence of shock, and less microbiological
confirmation of pneumonia (117, 69% vs. 71, 85%, p = 0.008), compared to patients with PaO2/FIO2
> 240. In multivariate logistic regression, PaO2/FIO2 ≤ 240 was independently associated with less
microbiological confirmation (adjusted odds-ratio 0.37, 95% confidence interval 0.15–0.89, p = 0.027).
The association between PaO2/FIO2 and microbiological confirmation of VAP was poor, with an area
under the ROC curve 0.645. Initial non-response to treatment and length of stay were similar between
both groups, while hospital mortality was higher in patients with PaO2/FIO2 ≤ 240. Conclusion:
Adding PaO2/FIO2 ratio ≤ 240 to the clinical and radiographic criteria does not help in the diagnosis of
VAP. PaO2/FIO2 ratio > 240 does not exclude this infection. Using this threshold may underestimate
the incidence of VAP.
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1. Introduction
Ventilator-associated pneumonia (VAP) remains the most frequent intensive care unit
(ICU)-acquired infection [1,2]. Its incidence ranges from 9% to 27% of ventilated patients depending
on diagnostic criteria [3]. VAP is associated with an increased length of stay, mortality and health care
costs [4,5].
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The diagnosis of VAP may be complex. Therefore, multiple efforts have been directed to overcome
these difficulties and to identify the most appropriate diagnostic strategies [6], including integrative
scoring systems that take into account multiple clinical data and microbiological findings.
The Clinical Pulmonary Infection Score (CPIS) score was developed to objectively diagnose VAP [6].
The score combines six variables: body temperature, white blood cell count, quantity and purulence
of tracheal secretions, chest radiograph, bacterial growth in tracheal secretions and oxygenation
(PaO2/FIO2 ≤ 240 in mmHg). However, the reported poor sensitivity and specificity of CPIS score in
most studies preclude its use as an accurate diagnostic strategy [7,8]. Similarly, the Centers for Disease
Control (CDC) and Prevention have proposed the inclusion of a decline in oxygenation, assessed by
a PaO2/FIO2 ratio ≤ 240, in the diagnostic criteria for VAP [9]. Current American guidelines define
pneumonia as the presence of a new or progressive radiological lung infiltrate plus the clinical evidence
that the infiltrate is of an infectious origin and a decline in oxygenation [2]. Indeed, the most reliable
evidence of an infectious origin in patients suspected of having VAP combines these criteria with
the microbiological identification of the potentially-pathogenic microorganisms (PPM) that cause
pneumonia [10].
To our knowledge, no studies have comprehensively evaluated the relationship between
microbiological diagnosis in populations with clinical suspicion of VAP and better or worse oxygenation,
as assessed by the PaO2/FIO2 ratio.
We hypothesized that patients with worse oxygenation would have more frequent microbiological
confirmation of VAP. In order to assess the adequacy of PaO2/FIO2 ≤ 240 to help in the diagnosis of
VAP, we compared the characteristics and outcomes of a real-life ICU population with suspected VAP
and PaO2/FIO2 ≤ or > 240, with special emphasis on microbiological confirmation.
2. Methods (Extended Information is Provided in Supplementary Materials)
2.1. Study Population
The study was conducted in six medical and surgical ICUs, overall comprising of 45 beds, at an
800-bed university hospital. Data were prospectively collected from 2007 to 2017. Investigators made
daily rounds of each ICU. Patients older than 18 years, mechanically-ventilated for 48 h or more, with
suspected VAP, were consecutively included into the study and only the first episode was analyzed.
We excluded patients with severe immune-suppression [11]. The institution’s Internal Review Board
approved the study (Comitè Ètic d’Investigació Clínica, registry number 2009/5427) and written informed
consent was obtained from patients or their next-of-kin.
2.2. Definition of Pneumonia, Microbiologic Processing, and Antimicrobial Treatment
The clinical suspicion of pneumonia was based on clinical criteria (new or progressive radiological
pulmonary infiltrate together with at least two of the following: (1) temperature >38 ◦C or < 36 ◦C;
(2) leukocytosis > 12,000/mm3 or leucopoenia < 4000/mm3; or (3) purulent respiratory secretions) [12,13].
The microbiologic evaluation included the collection of at least one lower respiratory airways
sample: tracheobronchial aspirates (TBAS) and/or bronchoscopic [14] or blind bronchoalveolar lavage
(BAL) [15] if possible, within the first 24 hours of inclusion [16]. The same sampling method was
performed on the third day if clinically indicated. Blood cultures and cultures from the pleural fluid
were also collected if clinically justified.
Microbiologic confirmation of pneumonia was defined by the presence of at least one PPM [17]
in the respiratory samples above pre-defined values (BAL > 104 and TBAS > 105 colony-forming
units/mL, respectively, or any value if the patient was under antibiotic treatment), in pleural fluid or in
blood cultures if an alternative cause of bacteremia was ruled out [18,19]. Microbiologic identification
and susceptibility testing were performed by standard methods [20].
The initial empiric antimicrobial treatment was administered in all patients according to the local
adaptation of guidelines [1,21], and subsequently revised according to the microbiologic results.
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The empiric antimicrobial treatment was considered appropriate when the isolated pathogens
were susceptible in vitro to at least one of the antimicrobials administrated at adequate dose [22].
The initial response to treatment was evaluated after 72 hours of antimicrobial treatment. In patients
with initial non-response to treatment [23,24], respiratory samples and blood cultures were obtained
again, and the empiric antimicrobial treatment was revised.
2.3. Assessment of the Systemic Inflammatory Response
We evaluated the serum levels of interleukin (IL)-6, IL-8, IL-10, tumour necrosis factor-alpha
(TNF-alpha), C-reactive protein (CRP), Procalcitonin (PCT), and mid-regional pro-adrenomedullin
(MR-proADM) within the first 24 hours and the third day after the diagnosis of pneumonia. All methods
for this analysis have been described in detail elsewhere [25,26].
2.4. Data Collection
All relevant data were collected at admission and at onset of pneumonia from the medical records
and bedside flow charts. Patients were followed until hospital discharge, death or up to 90-days after
the diagnosis of pneumonia. Septic shock [27] and acute respiratory distress syndrome (ARDS) [28]
were defined according to the previously described criteria.
2.5. Outcomes Variables
The rate of quantitative microbiological confirmation of patients with PaO2/FIO2 ≤ 240 was
compared with that of patients with PaO2/FIO2 > 240. The lowest value of PaO2/FiO2 on the day of
VAP diagnosis was considered for patients’ group allocation. Secondary outcomes were length of stay
and mortality, and 90-day survival after VAP diagnosis.
2.6. Statistical Analysis
Categorical and continuous data are presented as number (percentage) and as mean ± SD
(or median, inter-quartile range), respectively. Categorical variables were compared with the Chi-square
or Fisher’s exact tests. Quantitative continuous variables were compared using the unpaired Student’s
t-test or the Mann-Whitney test for normally and not normally distributed variables, respectively.
The Kaplan-Meier curves were used to compare survival in the two groups.
Univariate and multivariate logistic regression analyses were performed to assess the association
of PaO2/FIO2 ≤ 240 or > 240 with positive microbiology. Variables that showed a significant result
univariately (p < 0.10) were included in the corresponding multivariate logistic regression backward
stepwise model. Adjusted odds-ratio (OR) and 95% confidence intervals (CI) were calculated.
In addition, the association between PaO2/FIO2 at VAP onset as continuous variable and
quantitative microbiological confirmation was assessed using receiver-operator-characteristics (ROC)
curve analysis. The area under the ROC curve (AUC) with 95% confidence interval (CI), and the
optimal cut-off value of PaO2/FIO2 with sensitivity and specificity were calculated.
A two-sided p-value ≤ 0.05 was considered statistically significant. All statistical analyses were
performed using SPSS 22.0.0.0 (Chicago, IL, USA).
3. Results
3.1. Patients’ Characteristics
We prospectively identified 264 consecutive patients with suspected VAP during the study period;
we excluded nine cases because PaO2/FiO2 at onset of pneumonia was not available. Therefore,
we included 255; PaO2/FiO2 was ≤240 in 171 (67%) patients, and higher than this value in 84 (33%)
patients (Figure 1).
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Figure 1. Flow chart of the study population.
The characteristics of patients at ICU admission and pneumonia onset according PaO2/FIO2 are
summarized in Tables 1 and 2.
Table 1. Baseline characteristics of patients at ICU admission.
PaO2/FIO2 ≤ 240
n = 171
PaO2/FIO2 > 240
n = 84 p Value
Age, year 62 ± 16 61 ± 15 0.57
Sex, male/female, n 116/55 60/24 0.56
Alcohol abuse (current or former), n (%) 41 (24) 18 (21) 0.63
Smoking habit (current or former), n (%) 90 (53) 40 (48) 0.45
APACHE-II score 17 ± 6 19 ± 8 0.044
SAPS score 42 ± 15 45 ± 16 0.24
SOFA score 8 ± 3 8 ± 3 0.71
Co-morbidities, n (%)
Diabetes mellitus 41 (24) 19 (23) 0.81
Chronic renal failure 15 (9) 5 (6) 0.43
Solid cancer 19 (11) 10 (12) 0.85
Chronic heart disorders 54 (32) 28 (33) 0.78
Chronic lung disease 58 (34) 30 (24) 0.10
Chronic liver disease 27 (16) 9 (11) 0.27
Recent surgery, n (%) 81 (47) 43 (51) 0.57
Tracheotomy at admission, n (%) 16 (9) 11 (13) 0.37
Causes of ICU admission, n (%) 0.051
Post-operative 40 (23) 13 (16)
Hypoxemic respiratory failure 20 (12) 5 (6)
Decreased consciousness 31 (18) 17 (20)
Hypercapnic respiratory failure 16 (9) 5 (6)
Septic shock 12 (7) 10 (12)
Multiple trauma 12 (7) 16 (19)
Non-surgical abdominal disease 5 (3) 3 (4)
Acute coronary syndrome 10 (6) 2 (2)
Cardiac arrest 12 (7) 9 (11)
Other 6 (4) 4 (5)
Definition of abbreviations: APACHE: Acute Physiology and Chronic Health Evaluation; ICU: Intensive Care Unit;
SAPS: Simplified Acute Physiology Score; SOFA: Sepsis-related Organ Failure Assessment.
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Table 2. Characteristics of patients at pneumonia onset.
PaO2/FIO2 ≤ 240
n = 171
PaO2/FIO2 > 240
n = 84 p Value
Previous antibiotics, n (%) 139 (81) 66 (79) 0.61
Most frequent groups, n (%):
Penicillins 78 (46) 26 (31)
Cephalosporins 50 (29) 26 (31)
Quinolones 48 (28) 20 (24)
Carbapenems 23 (13) 14 (17)
Glycopeptides 28 (16) 9 (11)
Aminoglycosides 15 (9) 11 (13)
Clindamycin 14 (8) 11 (13)
Antifungals 6 (4) 2 (2)
Hospital stay before pneumonia, days * 7 (4–13) 7 (5–15) 0.34
ICU stay before pneumonia, days * 5 (3–9) 6 (4–10) 0.12
SOFA score 8 ± 3 7 ± 3 0.004
Bilateral pulmonary infiltrates, n (%) 55 (32) 19 (23) 0.11
ARDS criteria, n (%) 32 (19) 1 (1) <0.001
Pleural effusion, n (%) 56 (33) 18 (22) 0.10
PaO2/FiO2 161 ± 47 301 ± 49 <0.001
FiO2 0.55 ± 0.18 0.41 ± 11 <0.001
PEEP, cmH2O 7.4 ±3.4 7.8 ± 3.0 0.36
PaCO2, mmHg 41 ± 9 39 ± 7 0.066
pHa 7.40 ± 0.09 7.41 ± 0.07 0.33
Shock at onset of pneumonia, n (%) 96 (56) 32 (38) 0.007
Temperature 36.9 ± 1.4 37.0 ± 1.3 0.37
Serum creatinine, mg/dL 1.3 ± 1.0 1.2 ± 1.2 0.85
Blood haemoglobin, g/L 11 ± 2 10 ± 2 0.67
White blood cell count, L−9 14 ± 7 13 ± 6 0.11
Sodium, mEq/L 139 ± 6 141 ± 8 0.042
Potassium, mEq/L 4.0 ± 0.7 4.1 ± 0.5 0.75
CPIS day 1 7 ± 1 5 ± 1 <0.001
CPIS day 3 6 ± 2 5 ± 2 <0.001
* Results given as median (inter-quartile range). Definition of abbreviations: ICU: Intensive Care Unit; SOFA:
Sepsis-related Organ Failure Assessment; ARDS: Acute Respiratory Distress Syndrome; PaO2/FiO2: ratio of arterial
oxygen tension to inspired oxygen fraction; CPIS: Clinical Pulmonary Infection Score.
Compared to patients with PaO2/FIO2 > 240, those with PaO2/FIO2 ≤ 240 had a lower APACHE-II
score at ICU admission. However, at onset of pneumonia, patients with PaO2/FIO2 ≤ 240 had a higher
SOFA score and CPIS, in both cases due to the lower values of PaO2/FIO2, presented ARDS criteria and
shock more frequently, and had lower serum levels of sodium. Reasons for ICU admission were slightly
different between groups (p = 0.051), with higher proportions of multiple trauma and septic shock
among patients with PaO2/FIO2 > 240, and higher proportions of postoperative care and hypoxemic
respiratory failure in patients with PaO2/FIO2 ≤ 240. The evolution of PaO2/FiO2 at pneumonia onset
and at day 3 in both groups is shown in Figure 2.
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Figure 2. Evolution of PaO2/FiO2 from pneumonia onset (day 1) to day 3.
3.2. Microbiological Aetiology
The etiologic diagnosis of patients is shown in Table 3. The number of samples processed for
microbiology was similar between both groups. Pneumonia was microbiologically confirmed in
188 (74%) cases, with a lower rate of microbiological confirmation in patients with PaO2/FIO2 ≤ 240,
compared with those with PaO2/FIO2 > 240 (117, 69% vs. 71, 85%, p = 0.007; odds-ratio 0.40, 95% CI 0.21
to 0.79, p = 0.008). The multivariate logistic regression analysis showed that PaO2/FIO2 ≤ 240 mmHg
was independently associated with less microbiological confirmation of pneumonia (adjusted OR 0.37,
95% CI 0.15–0.89, p = 0.027). The association between PaO2/FIO2 and microbiological confirmation of
VAP was poor, although statistically significant, with an AUC 0.645 (95% CI 0.568 to 0.725, p = 0.040).
The optimal cut-off value of PaO2/FIO2 associated with microbiological confirmation of VAP was 223,
with sensitivity 45% and specificity 79%.
The most frequent pathogens identified were Pseudomonas aeruginosa, Gram-negative enteric
bacteria and Staphylococcus aureus, with no significant differences in the relative proportion of any
pathogen among patients with microbiological diagnosis of ICUAP.
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Table 3. Etiologic diagnosis of pneumonia according to PaO2/FIO2.
Pathogen PaO2/FIO2 ≤ 240n = 171
PaO2/FIO2 > 240
n = 84 p Value
Sample processed for microbiology, n (%)
Endotracheal aspirates 157 (92) 79 (94) 0.52
Bonchoalveolar lavage 38 (23) 21 (25) 0.62
Blood 126 (74) 58 (69) 0.44
Pleural fluid 18 (11) 5 (6) 0.23
Positive microbiology, n (%) 117 (69) 71 (85) 0.007
Gram-positive bacteria, n (%) 37 (32) 23 (32) 0.96
MS Staphylococcus aureus 18 (15) 17 (24) 0.20
MR Staphylococcus aureus 12 (10) 4 (6) 0.41
Streptococcus pneumoniae 8 (7) 2 (3) 0.39
Gram-negative enteric bacteria, n (%) 39 (33) 16 (23) 0.16
Enterobacter spp 7 (6) 2 (3) 0.53
Klebsiella spp 11 (9) 6 (9) 0.78
Escherichia coli 9 (8) 2 (3) 0.62
Proteus spp 2 (2) 2 (3) 0.99
Citrobacter spp 3 (3) 3 (4) 0.84
Serratia spp 8 (7) 4 (6) 0.97
Morganella morganii 1 (1) 0 (0) 0.80
Non-fermentating gram-negative bacilli 38 (32) 29 (41) 0.32
Stenotrophomonas maltophilia 7 (6) 3 (4) 0.85
Pseudomonas aeruginosa 31 (27) 26 (37) 0.19
Other gram-negative bacteria
Moraxella catarrhalis 2 (2) 0 (0) 0.71
Haemophilus influenzae 3 (3) 4 (6) 0.50
Fungi, n (%) 2 (2) 1 (1) 0.66
Aspergillus spp 2 (2) 1 (1) 0.66
Others, n (%) 0 (0) 1 (5) -
Polymicrobial aetiology * 19 (11) 9 (11) 0.91
* Polymicrobial pneumonia was defined when more than one potentially-pathogenic microorganism was identified
as causative agents.
3.3. Systemic Inflammatory Response
The serum levels of all inflammatory biomarkers at pneumonia onset and at day 3 are shown in
Table 4. Patients with PaO2/FIO2 ≤ 240 had higher serum levels of Procalcitonin at pneumonia onset,
without any significant difference in the remaining biomarkers.
Table 4. Serum levels of inflammatory biomarkers *.
n † PaO2/FIO2 ≤ 240n = 171 n †
PaO2/FIO2 > 240
n = 84 p Value
C-reactive protein day 1, mg/dL 164 13 (6–21) 81 11 (4–19) 0.13
C-reactive protein day 3, mg/dL 149 11 (4–19) 78 9 (5–15) 0.078
IL-6 day 1, pg/mL 89 168 (72–431) 36 109 (41–229) 0.077
IL-6 day 3, pg/mL 75 91 (19–204) 32 78 (33–183) 0.98
IL-8 day 1, pg/mL 89 108 (64–214) 36 94 (57–137) 0.17
IL-8 day 3, pg/mL 75 76 (41–145) 32 99 (63–170) 0.15
TNF-alpha day 1, pg/mL 89 8 (5–17) 36 7 (5–14) 0.73
TNF-alpha day 3, pg/mL 75 7 (4–14) 32 8 (5–15) 0.61
Procalcitonin day 1, ng/mL 90 0.45 (0.14–1.37) 37 0.19 (0.07–0.59) 0.037
Procalcitonin day 3, ng/mL 78 0.30 (0.10–1.06) 34 0.20 (0.08–0.74) 0.57
MR-proADM day 1, nmol/L 98 1.27 (0.33–2.22) 40 1.16 (0.65–2.23) 0.84
MR-proADM day 3, nmol/L 87 1.36 (0.38–2.37) 37 1.08 (0.61–2.04) 0.92
* Results are given as median (inter-quartile range). † Number of cases with blood samples processed for each
inflammatory biomarker and group. Definition of abbreviations: IL: interleukin; TNF: tumor necrosis factor;
MR-proADM: mid-regional pro-adrenomedullin.
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3.4. Empiric Antibiotic Treatment and Outcome Variables
Initial non-response to treatment, length of stay and ICU mortality were similar between both
groups (Table 5).
Table 5. Outcome variables.
PaO2/FIO2 ≤ 240
n = 171
PaO2/FIO2 > 240
n = 84 p Value
ICU stay, days * 19 (12–29) 18 (13–32) 0.75
Hospital stay, days * 34 (19–56) 43 (21–56) 0.34
Non-response to treatment, n (%) 94 (55) 48 (57) 0.74
ICU mortality, n (%) 53 (31) 18 (24) 0.11
Hospital mortality, n (%) 71 (42) 24 (29) 0.044
Ventilator-free days at day 28 * 3 (0–21) 17 (0–24) 0.022
Causes of death within 90 days: 0.28
Shock, n (%) 52 (74) 14 (58)
Refractory hypoxemia, n (%) 4 (6) 2 (8)
Order do-not-resuscitate, n (%) 1 (1) 2 (8)
Brain anoxia, n (%) 11 (16) 6 (25)
Others, n (%) 2 (3) 0 (0)
* Results given as median (inter-quartile range). Definition of abbreviations: ICU: Intensive Care Unit.
Hospital mortality was higher, and the ventilator-free days were lower, in patients with PaO2/FIO2
≤ 240, while 90-day survival tended to be lower in this group (p = 0.070, Figure 3).
Figure 3. Survival curves at 90 days.
4. Discussion
To the best of our knowledge, this is the first study investigating the relationship between
quantitative microbiological confirmation and oxygenation in a prospective cohort of patients
mechanically ventilated and suspected of having VAP. We found that PaO2/FIO2 ≤ 240 was associated
with less microbiological confirmation in this subgroup of patients. In addition, patients with worse
oxygenation had higher hospital mortality.
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The diagnosis of VAP yields on clinical criteria; however, due to their potential subjectivity,
other parameters has been proposed in order to better define VAP episodes [29]. Over the last years,
due to an excess of antibiotic treatment, the United States Critical Care Collaborative Societies and the
Department of Health and Human Services have proposed the implementation of “ventilator-associated
complications” and “ventilator-associated infections” [30]. However, the use of “more objective”
criteria such as chest X-ray and oxygenation has important limitations. Chest X-rays may be difficult
to interpret in ICU patients due to multiple non-infectious causes such as congestive heart failure,
atelectasis, prior chronic lung disease, or ARDS.
Microbiological confirmation is probably the best matching to assess VAP diagnosis quality [10].
We hypothesized that patients with more impaired oxygenation would have more frequently etiologic
diagnosis and therefore they would be considered as definitive VAP episodes. Surprisingly our
findings demonstrated the opposite. We previously reported that negative microbiology in patients
with both community-acquired and ICU-acquired pneumonia was associated with renal and cardiac
co-morbidities [31,32]. These studies suggested that some of these cases might also represent, at least
in part, fluid overload because of renal failure or congestive heart failure added to the underlying
inflammatory process potentially mimicking pneumonia. These conditions often exhibit more severe
deterioration of oxygenation, thus possibly explaining the association of lower PaO2/FIO2 with less
microbiological confirmation of VAP. However, lack of detection of a PPM would not preclude existence
of an infection since many patients are previously treated with antibiotics. Therefore, until more
specific diagnostic criteria are available, initiation of antimicrobial treatment should still be based on
the clinical signs of infection together with radiographic criteria.
The use of oxygenation has been proposed in many diseases as a criterion for diagnosis. Indeed,
in case of ARDS PaO2/FIO2 ratio is both a diagnostic and stratification tool [28,33]. Therefore, since
pneumonia is the most frequent cause of ARDS [33], PaO2/FIO2 ratio has also been considered for
pneumonia diagnosis too. Unfortunately, although PaO2/FIO2 might be a good parameter of severity,
it might lead clinicians to over treat patients. In many situations of daily clinical practice, the use of
PaO2/FIO2 ratio might trigger antibiotics start when they are probably not needed, and conversely
patients with clear infiltrates in the X-rays but without major oxygenation derangements might
preclude that the patient is not developing a VAP. In our population, 33% of suspected VAP episodes
had a PaO2/FIO2 >240. Therefore, the use of this threshold of PaO2/FIO2 in the diagnosis probably
would have underestimated the incidence of VAP. This has important implications, either in the
development of antimicrobial resistance due to unnecessary treatment, and an increase in mortality
due to inappropriate (or none) antibiotic treatment. Using PaO2/FIO2 may be important to stratify
patients’ severity in controlled clinical trials, and probably for an earlier or more aggressive treatment,
as we report higher hospital mortality for those patients with worse oxygenation. We think, however,
that patients with higher PaO2/FIO2 should not be excluded from clinical trials dealing with VAP.
One probable reason to point out oxygenation as a diagnosis marker is due to a wrong interpretation
of CPIS as a clinical marker for VAP [6]. The CPIS can be a useful tool for severity identification
when the patient has been diagnosed of VAP and can help to address patients’ response to treatment.
Luna et al. using PaO2/FIO2 ratio could demonstrate that this was the best parameter for patients’
stratification of treatment response and a marker of clinical cure [34]. Moreover, we have previously
reported that lack of improvement of PaO2/FIO2 was among the best predictors for adverse outcomes
in ICU-acquired pneumonia [24]. This, however, faces against the use of PaO2/FIO2 as a diagnostic
criterion, especially in some subsets of patients such as those with multiple trauma, surgery, or major
burns [8]. Indeed, we found in the present study that patients with postoperative VAP episodes
presented more hypoxemia compared to patients with multiple trauma. On the other hand, the recent
HAP/VAP International guidelines [35] made a weak recommendation for short antibiotic courses in
patients with low CPIS (i.e., 6 or less). However, this does not seem to be related to diagnosis purposes.
Diagnosis of VAP including oxygenation has not been universally accepted by many authors.
In a European cohort study conducted in 465 patients with VAP, worsening oxygenation was present
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in 3 out of 4 patients [36], whilst Martin-Loeches et al. found it in two-thirds of their patients with
VAP [37]. Similar to severe CAP [38], oxygenation can be and probably should be taken as a severity
criteria similar to septic shock development, but it should not substitute current diagnostic parameters
widely used. Several studies performed over the last decade have found that prompt antibiotic therapy
was the most important determinant for improved outcomes in a general sepsis population [39].
It does not seem reasonable to add a test that based on our results would delay and probably mislead
VAP diagnosis.
The current study has important strengths. It includes a long cohort of patients prospectively
collected and without significant loss of follow-up due to a careful surveillance with a dedicated
research team. In all the patients, blood gases were taken at the moment of diagnosis based on local
protocols. Because of inaccuracy to assess the actual FiO2 in non-intubated patients, we did not include
cases of non-ventilator ICU-acquired pneumonia [40]. Moreover, all patients had at least one lower
respiratory tract sample processed for culture at onset of pneumonia, and the frequency and type of
previous antibiotic treatment is reported, without differences related to severity of oxygenation in both
variables. An additional value for this study is the acquisition of inflammatory markers at the onset
of pneumonia and after three days of antibiotic treatment. However, we have to acknowledge some
limitations. The most important would be the single centre analysis, which might limit reproducibility
of the results. However, since the same research team worked on the project during the inclusion
period, the study appears reliable in terms of diagnosis and homogeneity. Second, we did not collect
blood gas data at ICU admission and therefore cannot assess the evolution of oxygenation before
patients were suspected of having VAP.
5. Conclusions
In conclusion, we have found that adding PaO2/FIO2 ratio ≤ 240 to the clinical and radiographic
criteria does not help in the diagnosis of VAP. PaO2/FIO2 ratio > 240 does not exclude this infection.
Using this threshold may underestimate the incidence of VAP. Changing this paradigm might have
beneficial effects on the early antibiotic treatment for VAP.
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